Table 2 Comparison of the median survival time of patients with or without portal vein thrombosis and/or distant metastasis
From: The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma
Groups | n | Mean (95% Confidence Interval) | P value | |
|---|---|---|---|---|
HCC without portal vein thrombosis/metastasis | TACE | 22 | 15.94 (11.87–20.01) | 0.027 |
TACE + Sorafenib | 25 | 29.09 (22.76–35.41) | ||
HCC with portal vein thrombosis/metastasis | TACE | 23 | 12.00 (9.96–16.02) | 0.041 |
TACE + Sorafenib | 20 | 27.20 (19.07–35.32) |